The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Cash and cash equivalents at beginning of period | 10,792,172 | 1,037,320 | - |
| Gain on loan forgiveness | - | 0 | 0 |
| Net loss | -2,247,669 | -2,228,358 | -4,957,165 |
| Depreciation and amortization | 25,460 | 25,868 | 93,405 |
| Share-based compensation | 399,862 | 404,425 | 325,217 |
| Accounts and other receivable | -217,387 | 359,828 | 18,159 |
| Prepaid expenses and other current assets | 155,922 | -34,477 | -73,355 |
| Accounts payable and accrued liabilities | -326,452 | 402,422 | -1,117,921 |
| Proceeds from issuance of series b-1 preferred shares-Series B1Preferred Stock | - | 0 | 8,340,000 |
| Net cash used in operating activities | -2,087,334 | -1,720,994 | -5,601,268 |
| Proceeds from issuance of common shares | 3,497,825 | 220,501 | 7,497,133 |
| Payments for issuance costs of common shares and warrants-Preferred Stock | - | 0 | 215,157 |
| Payment for issuance costs of warrants | - | 0 | 23,446 |
| Repayment of debt | - | 0 | 0 |
| Proceeds from issuance of series a-1 preferred shares and warrants | 0 | 0 | 1,540,820 |
| Payments for issuance costs of common shares-Common Stock And Warrants | 142,406 | 34,018 | 294,935 |
| Net cash provided by financing activities | 3,355,419 | 186,483 | 16,844,415 |
| Effect of exchange rate changes on cash and cash equivalents | -8,509 | -35,007 | 81,223 |
| Net change in cash and cash equivalents | 1,259,576 | -1,569,518 | 11,324,370 |
| Cash and cash equivalents at end of period | 12,051,748 | 10,792,172 | - |
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)